|Mr. Werner Baumann||Chairman of Management & CEO||3.57M||N/A||55|
|Mr. Johannes M. Dietsch||Head of Fin. Dept, CFO - Asia/Pacific Region & Member of Management Board||1.9M||N/A||55|
|Mr. Liam Condon||CEO of Bayer Cropscience & Member of Management Board||1.97M||N/A||49|
|Dr. Kemal Malik||Head of Innovation & Member of Management Board||1.9M||N/A||55|
|Dr. Hartmut Klusik||Head of HR, Technology & Sustainability, Labor Director and Member of Management Board||1.96M||N/A||61|
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment provides nonprescription over-the-counter products in the dermatology, nutritional supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care, and sun protection categories. The Crop Science segment offers products in the areas of seeds and plant traits, crop protection, and nonagricultural pest control. The Animal Health segment provides prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; and raw materials for coatings, adhesives, and sealants; and by-products of polyether production and of chlorine production and use. The company has strategic partnerships with Broad Institute and German Cancer Research Center, as well as strategic research alliance with University of Oxford; and a multi-target endometriosis alliance with Evotec AG. It also has a strategic alliance with Rothamsted Research; and a research agreement with Vanderbilt University Medical Center to develop therapies for kidney diseases. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Bayer Aktiengesellschaft’s ISS Governance QualityScore as of February 1, 2018 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 1; Compensation: 2.